{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:58:40Z","timestamp":1761490720256},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Biotechnology, India","award":["GAP-2158"],"award-info":[{"award-number":["GAP-2158"]}]},{"name":"CSIR fast-track translational (CSIR-FTT) project","award":["MLP-5008"],"award-info":[{"award-number":["MLP-5008"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jpba.2018.12.027","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T11:55:19Z","timestamp":1545134119000},"page":"1-5","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Impurity profiling of anticancer preclinical candidate, IIIM-290"],"prefix":"10.1016","volume":"166","author":[{"given":"Vikas","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deendyal","family":"Bhurta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip B.","family":"Bharate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram A.","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali S.","family":"Bharate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.12.027_bib0005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpba.2017.04.014","article-title":"Isolation, identification and characterization of potential impurities of anidulafungin","volume":"141","author":"Zhao","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.12.027_bib0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jpba.2017.11.039","article-title":"Development and validation of a new HPLC-MS method for meglumine impurity profiling","volume":"149","author":"Martano","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.12.027_bib0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpba.2016.01.057","article-title":"Impurity profiling of L-methionine by HPLC on a mixed mode column","volume":"122","author":"Kuhnreich","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jpba.2018.12.027_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2006.10.010","article-title":"Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications","volume":"59","author":"Basak","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jpba.2018.12.027_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2006.10.003","article-title":"Assuring quality of drugs by monitoring impurities","volume":"59","author":"Ahuja","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jpba.2018.12.027_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2006.10.005","article-title":"Strategies for the investigation and control of process-related impurities in drug substances","volume":"59","author":"Argentine","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jpba.2018.12.027_bib0035","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00216-003-2140-6","article-title":"Chemical and analytical characterization of related organic impurities in drugs","volume":"377","author":"Gorog","year":"2003","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2018.12.027_bib0040","first-page":"903","article-title":"International conference on harmonization impurity guidelines- the industry perspective","volume":"34","author":"Rousseau","year":"2000","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.jpba.2018.12.027_bib0045","unstructured":"ICH, Harmonised Tripartite Guideline: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological\/biological Entities) Q11, (2012 (Accessed 4 June 2018)) http:\/\/www.ich.org\/products\/guidelines\/quality\/article\/quality-guidelines.html."},{"key":"10.1016\/j.jpba.2018.12.027_bib0050","unstructured":"ICH, Impurities in new drug substances-Q3A(R2), (2006 (Accessed 4 June 2018)) http:\/\/www.ich.org\/products\/guidelines\/quality\/quality-single\/article\/impurities-in-new-drug-substances.html."},{"key":"10.1016\/j.jpba.2018.12.027_bib0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/op300268u","article-title":"Risk assessment of genotoxic impurities in new chemical entities: strategies to demonstrate control","volume":"17","author":"Teasdale","year":"2013","journal-title":"Org. Process Res. Dev."},{"issue":"9","key":"10.1016\/j.jpba.2018.12.027_bib0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1517\/17425247.2013.783563","article-title":"Impact of preformulation on drug development","volume":"10","author":"Bharate","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"issue":"12","key":"10.1016\/j.jpba.2018.12.027_bib0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197303222881211","article-title":"Penicillamine-an Anglo-American adventure in the treatment of rheumatoid arthritis","volume":"288","author":"Jaffe","year":"1973","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jpba.2018.12.027_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0731-7085(03)00256-5","article-title":"Determination of MPTP, a toxic impurity of pethidine","volume":"33","author":"Quaglia","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.12.027_bib0075","unstructured":"FDA updates on valsartan recalls, (2018 (Accessed 24 September 2018)) https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm613916.htm."},{"issue":"4","key":"10.1016\/j.jpba.2018.12.027_bib0080","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/acs.jmedchem.7b01765","article-title":"Discovery and preclinical development of IIIM-290, an orally active potent cyclin-dependent kinase inhibitor","volume":"61","author":"Bharate","year":"2018","journal-title":"J. Med. Chem."},{"issue":"42","key":"10.1016\/j.jpba.2018.12.027_bib0085","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.tetlet.2017.09.005","article-title":"Anti-inflammatory chromone alkaloids and glycoside from Dysoxylum binectariferum","volume":"58","author":"Kumar","year":"2017","journal-title":"Tetrahedron Lett."},{"issue":"7","key":"10.1016\/j.jpba.2018.12.027_bib0090","doi-asserted-by":"crossref","first-page":"8365","DOI":"10.1021\/acsomega.8b00801","article-title":"Selection of a water-soluble salt form of a preclinical candidate, IIIM-290: multiwell-plate salt screening and characterization","volume":"3","author":"Kumar","year":"2018","journal-title":"ACS Omega"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518321952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518321952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T10:38:59Z","timestamp":1550313539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518321952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":18,"alternative-id":["S0731708518321952"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.12.027","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impurity profiling of anticancer preclinical candidate, IIIM-290","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}